Adaptimmune’s Novel Gene Editing Approach; Do iPSC-derived αβT Cells Have an Advantage Over NK Cells? Thoughts on Adaptimmune’s Allogeneic Platform Virtual Event 2021

On Thursday, September 9, Adaptimmune held a virtual event (presentation) discussing the scope of their recent Genentech (Roche) collaboration. Additionally, management highlighted Adaptimmune’s strategy to knockout recombination-activating gene (RAG) in order to eliminate native TCR expression, while announcing the completion of a new allogeneic manufacturing facility by YE 2022 in Milton Park, UK. Below, Celltelligence provides insights on how Adaptimmune’s collaboration with Genentech (Roche) could potentially impact GSK’s TCR-T strategy, Adaptimmune’s decision to develop iPSC-derived αβT cells, and which alternative lymphodepletion regimens could be used for their allogeneic products.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.